

Hong Kong Exchanges and Clearings Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

TERMINATION OF PLACING AGREEMENT

The Board announces that as certain conditions precedent to the Placing Agreement have not been fulfilled, the Placing Agreement expired and was terminated on 17 February 2013.

Reference is made to the announcements of the Company dated 17 February 2012 and 10 July 2012 (the “**Placing Announcement**”) and the circular of the Company dated 24 May 2012 in relation to the placing of not more than 192,500,000 H Shares through the Placing Agent on a best efforts basis under the Placing Agreement. Capitalized terms used in this announcement shall have the same meaning as those defined in the Placing Announcement unless otherwise stated.

Pursuant to the Placing Agreement, it shall terminate one year from the date of its execution if Completion does not occur before expiration of that period unless otherwise agreed by the parties. As certain conditions precedent to the Placing Agreement have not been fulfilled and Completion has not taken place, the Placing Agreement expired and terminated on 17 February 2013. No New Placing H Shares will be issued by the Company under the Placing Agreement accordingly.

The Directors are of the view that the lapse of the Placing Agreement has no material adverse impact on the business operation and financial position of the Group as a whole.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Wang Shuxin
Chairman

Tianjin, the PRC
15 February 2013

As at the date of this announcement, the Board comprises three executive Directors, being Mr. Wang Shuxin, Mr. Hao Zhihui and Mr. Zhang Chunsheng; three non-executive Directors, being Mr. Feng Enqing, Mr. Xie Guangbei and Mr. Ou Linfeng and three independent non-executive Directors, being Mr. Guan Tong, Mr. Wu Chen and Mr. Cao Kai.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

The announcement will remain on the GEM website at <http://www.hkgem.com> at the “Latest Company Announcements” page for 7 days from the date of its publication. This announcement will also be published and remain on the website of the Company at www.bioteda.com.